Stockscreener 앱 받기
42.79
3.60%
-1.60
시간 외 거래:
42.40
-0.39
-0.91%
Hims Hers Health Inc 주식(HIMS)의 최신 뉴스
Promising Healthcare Stocks To Watch NowNovember 2nd - MarketBeat
Hims & Hers Health, Inc. Reports Strong Growth and Strategic Optimism - TipRanks
White House nears deal to lower prices for weight loss drugs Wegovy and Zepbound - AOL.com
Best Healthcare Stocks To Follow TodayNovember 4th - MarketBeat
OMCL vs. HIMS: Which Stock Is the Better Value Option? - sharewise.com
Hims & Hers Eyes Major Weight-Loss Breakthrough With Potential Novo Nordisk Wegovy Deal - Yahoo! Finance Canada
Hims & Hers gains as analysts welcome talks with Novo for Wegovy sales - MSN
Deutsche Bank Adjusts Hims & Hers Health Price Target to $42 From $48, Maintains Hold Rating - MarketScreener
HIMS Q3 Deep Dive: Personalized Offerings and Strategic Expansion Shape Telehealth Growth - TradingView
Hims & Hers rises after Q3 revenue beat - TradingView
BTIG Research Reiterates Buy Rating for Hims & Hers Health (NYSE:HIMS) - MarketBeat
Hims & Hers Health (NYSE:HIMS) Price Target Raised to $32.00 - MarketBeat
Hims and Hers tops revenue estimates as telehealth provider attracts more users - MSN
Earnings live: Palantir stock rises modestly on strong results, Hims & Hers stock surges - Yahoo Finance
Hims Shares Rise on Talks to Offer Novo’s New Obesity Pill - Bloomberg
Biggest stock movers Tuesday: PLTR, SRPT, and more - MSN
Hims & Hers Plunges After Novo Split, Eyes Global Push - Value The Markets
Hims & Hers Stock (HIMS) Soars on Potential Deal to Offer Novo Nordisk’s Wegovy - TipRanks
Decoding Hims & Hers Health Inc (HIMS): A Strategic SWOT Insight - GuruFocus
Hims & Hers Health Inc (HIMS) Q3 2025 Earnings Call Highlights: Robust Revenue Growth and ... - Yahoo Finance
Hims & Hers Health Reports Strong Q3 2025 Growth - TipRanks
Palantir, Kimberly-Clark, Hims & Hers, Navitas And Cipher Mining: Why These 5 Stocks Are On Investors' Radars Today - Benzinga
Key facts: Novo Nordisk Q3 revenue up 9.4%; bids $8.5B for Metsera; Hims launches semaglutide - TradingView
Hims Hers (HIMS) Q3 2025 Earnings Call Transcript - The Globe and Mail
Earnings call transcript: Hims & Hers Health Q3 2025 misses EPS, stock rebounds - Investing.com Philippines
Live: Hims & Hers Earnings Coverage - 24/7 Wall St.
Novo Nordisk’s weight-loss drug Wegovy could soon have a new sales outlet in the U.S. - MarketWatch
Hims & Hers Health (HIMS) Surges After Hours on Robust Q3 and Renewed Novo Nordisk (NVO) Wegovy Talks - FinancialContent
Hims & Hers Health, Inc. (HIMS) Q3 Earnings Match Estimates - Yahoo! Finance Canada
Hims & Hers Health in discussions with Novo Nordisk to sell Wegovy - Seeking Alpha
Hims & Hers in talks to offer Novo’s new obesity pill - Modern Healthcare
Hims & Hers Health Third-Quarter Revenue Jumps as Subscribers Grow - The Wall Street Journal
Hims & Hers Health Q3 revenue tops estimates as subscriber growth jumps - Investing.com Philippines
Hims & Hers Health rises after narrowing 2025 EBITDA guidance, Q3 EPS miss - Seeking Alpha
After-hours movers: Palantir, Hims & Hers Health, Sarepta Therapeutics, Sanmina - Investing.com Canada
Hims & Hers Health (NYSE:HIMS) Issues Quarterly Earnings Results, Meets Expectations - MarketBeat
Hims & Hers Health Q3 revenue tops estimates as subscriber growth jumps By Investing.com - Investing.com South Africa
Hims and Hers beats revenue estimates on strong subscriber growth - Yahoo Finance
Hims & Hers Q3 2025 Earnings: Revenue Beats Forecasts on Subscriber GrowthNews and Statistics - IndexBox
Hims & Hers Stock Pops After Q3 Earnings: Here's WhyHims & Hers Health (NYSE:HIMS) - Benzinga
Hims and Hers up after beating quarterly revenue estimates - TradingView
Hims & Hers Health’s (NYSE:HIMS) Q3 Sales Top Estimates - Yahoo Finance
Stock Market Today: Palantir, Vertex, and Hims & Hers Report After the Closing Bell - TheStreet
Hims and Hers misses quarterly profit estimates - Yahoo! Finance Canada
Hims rises on revenue beat, discloses it’s again in partnership talks with Novo - Sherwood News
How we’re reaching more customers with a new standard of care - Hims & Hers Newsroom
Hims and Hers Beats Revenue Estimates on Strong Subscriber Growth - US News Money
Earnings Flash (HIMS) Hims & Hers Health, Inc. Reports Q3 Revenue $599.0M, vs. FactSet Est of $580.2M - MarketScreener
Hims & Hers Health, Inc. Reports Third Quarter 2025 Financial Results - The Joplin Globe
Notable Monday Option Activity: PFGC, GRPN, HIMS - Nasdaq
Hims & Hers Health Stock Jumps After-Hours As Q3 Growth, Novo Nordisk Talks Fuel Bullish Retail Bets - Stocktwits
Hims & Hers Q3 Preview: GLP-1 Drug Expansion Draws Investor Focus - Stocktwits
OMCL vs. HIMS: Which Stock Should Value Investors Buy Now? - Yahoo Finance
PREVIEW: Hims & Hers dips; focus on weigth-loss drug - TradingView
Hers Health, Inc. Reports Third Quarter 2025 Financial Results - Hims Investor Relations
Stock Market Today: Dow Jones, Nasdaq Futures Rise After Stellar October Gains— Micron Technology, Palantir, Hims & Hers In Focus (UPDATED) - Benzinga
Hims & Hers Stock Seeks Support as Earnings Casts a Shadow - AskTraders.com
Intellectus Partners LLC Buys Shares of 61,036 Hims & Hers Health, Inc. $HIMS - MarketBeat
7,345 Shares in Hims & Hers Health, Inc. $HIMS Purchased by W.G. Shaheen & Associates DBA Whitney & Co - MarketBeat
1.53%
0.45%
자본화:
|
볼륨(24시간):